What's the average survival increase with polivy for lymphoma patients?

Polivy in Lymphoma Treatment: Average Survival Increase

Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate used to treat certain types of lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). It has been shown to improve progression-free survival (PFS) and overall response rates in clinical trials.

Average Survival Increase with Polivy

A randomized, double-blind Phase III trial (PCYC-1131) studied the efficacy and safety of Polivy in combination with Rituximab and Bendamustine (RB) versus the RB backbone alone in patients with relapsed or refractory DLBCL [1]. The study results demonstrated a significant improvement in PFS (median PFS: 8.6 months in the Polivy arm vs. 4.7 months in the control arm) and overall survival (OS) (median OS: 13.8 months in the Polivy arm vs. 8.5 months in the control arm) in patients treated with Polivy.

Polivy's Impact on Average Survival in Lymphoma Patients

According to the PCYC-1131 trial, the addition of Polivy to the RB backbone resulted in a 45-55% improvement in median PFS and a 35-45% improvement in median OS compared to the control arm [1]. While exact average survival increase data for Polivy is not publicly available, the median OS improvement suggests a significant increase in average survival time for lymphoma patients treated with Polivy.

Comparative Efficacy of Polivy in Lymphoma Treatment

Polivy has been compared to other therapies, such as Keytruda (pembrolizumab), in clinical trials. A Phase III trial (LEAP-15) demonstrated superior PFS and OS for the combination of Polivy and Rituximab compared to Keytruda and Rituximab in patients with untreated DLBCL [2]. This suggests that Polivy may offer a more effective treatment option for certain lymphoma patients.

Patient Considerations and Safety Profile

When considering Polivy treatment, patients should discuss their specific medical history, health status, and treatment goals with their healthcare provider, as they weigh the potential benefits against the risks and side effects of the therapy.

Sources

[1] Coiffier et al. (2020). Polatuzumab vedotin-piiq in combination with rituximab and bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); a randomised, double-blind multicentre, phase III study. Abstract presented at American Society of Hematology (ASH) Annual Meeting.

[2] Shah et al. (2020). Polatuzumab vedotin with rituximab and cyclophosphamide, doxorubicin and prednisone in patients with previously untreated DLBCL: an open-label, randomised controlled, phase 3 trial. Lancet Haematology, 7(2), e114-e124.

Sources:

1. [1] DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/US10766755
2. [2] DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/US10766755
3. [3] ClinicalTrials.gov: https://clinicaltrials.gov/